Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 355

1.

In vitro and in vivo characterization of equine herpesvirus type 1 (EHV-1) mutants devoid of the viral chemokine-binding glycoprotein G (gG).

von Einem J, Smith PM, Van de Walle GR, O'Callaghan DJ, Osterrieder N.

Virology. 2007 May 25;362(1):151-62. Epub 2007 Jan 23.

2.

Equine herpesvirus 1 mutants devoid of glycoprotein B or M are apathogenic for mice but induce protection against challenge infection.

Neubauer A, Beer M, Brandmüller C, Kaaden OR, Osterrieder N.

Virology. 1997 Dec 8;239(1):36-45.

3.

Herpesvirus chemokine-binding glycoprotein G (gG) efficiently inhibits neutrophil chemotaxis in vitro and in vivo.

Van de Walle GR, May ML, Sukhumavasi W, von Einem J, Osterrieder N.

J Immunol. 2007 Sep 15;179(6):4161-9.

4.
5.

EHV-1 glycoprotein D (EHV-1 gD) is required for virus entry and cell-cell fusion, and an EHV-1 gD deletion mutant induces a protective immune response in mice.

Csellner H, Walker C, Wellington JE, McLure LE, Love DN, Whalley JM.

Arch Virol. 2000;145(11):2371-85.

PMID:
11205124
6.

Contribution of gene products encoded within the unique short segment of equine herpesvirus 1 to virulence in a murine model.

Frampton AR Jr, Smith PM, Zhang Y, Matsumura T, Osterrieder N, O'Callaghan DJ.

Virus Res. 2002 Dec;90(1-2):287-301.

PMID:
12457983
7.

The role of secreted glycoprotein G of equine herpesvirus type 1 and type 4 (EHV-1 and EHV-4) in immune modulation and virulence.

Thormann N, Van de Walle GR, Azab W, Osterrieder N.

Virus Res. 2012 Oct;169(1):203-11. doi: 10.1016/j.virusres.2012.07.029. Epub 2012 Aug 8.

PMID:
22902480
8.

Pathogenicity and immunogenicity of equine herpesvirus type 1 mutants defective in either gI or gE gene in murine and hamster models.

Tsujimura K, Yamanaka T, Kondo T, Fukushi H, Matsumura T.

J Vet Med Sci. 2006 Oct;68(10):1029-38.

9.

An equine herpesvirus type 1 recombinant with a deletion in the gE and gI genes is avirulent in young horses.

Matsumura T, Kondo T, Sugita S, Damiani AM, O'Callaghan DJ, Imagawa H.

Virology. 1998 Mar 1;242(1):68-79.

10.

Equine herpesvirus-1 strain KyA, a candidate vaccine strain, reduces viral titers in mice challenged with a pathogenic strain, RacL.

Colle CF 3rd, Tarbet EB, Grafton WD, Jennings SR, O'Callaghan DJ.

Virus Res. 1996 Aug;43(2):111-24.

PMID:
8864201
11.
12.

The equine herpesvirus 1 IR6 protein influences virus growth at elevated temperature and is a major determinant of virulence.

Osterrieder N, Neubauer A, Brandmüller C, Kaaden OR, O'Callaghan DJ.

Virology. 1996 Dec 15;226(2):243-51.

13.

[Mutations in the US2 and glycoprotein B genes of the equine herpesvirus 1 vaccine strain RacH have no effects on its attenuation].

Neubauer A, Meindl A, Osterrieder N.

Berl Munch Tierarztl Wochenschr. 1999 Sep;112(9):351-4. German.

PMID:
10507185
14.
15.
16.
17.

Meningoencephalitis in mice infected with an equine herpesvirus 1 strain KyA recombinant expressing glycoprotein I and glycoprotein E.

Frampton AR Jr, Smith PM, Zhang Y, Grafton WD, Matsumura T, Osterrieder N, O'Callaghan DJ.

Virus Genes. 2004 Aug;29(1):9-17.

PMID:
15215680
19.

In vitro characterization of EHV-4 gG-deleted mutant.

Azab W, El-Sheikh A, Abdel-Gawad A.

Virus Genes. 2012 Feb;44(1):109-11. doi: 10.1007/s11262-011-0677-6. Epub 2011 Sep 29.

PMID:
21960433
20.

Argentine strain of equine herpesvirus 1 isolated from an aborted foetus shows low virulence in mouse respiratory and abortion models.

Galosi CM, Barbeito CG, Vila Roza MV, Cid de la Paz V, Ayala MA, Corva SG, Etcheverrigaray ME, Gimeno EJ.

Vet Microbiol. 2004 Oct 5;103(1-2):1-12.

PMID:
15381260
Items per page

Supplemental Content

Write to the Help Desk